Biogen Idec and Sangamo BioSciences have announced an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin.
The agreement will enable Biogen to leverage Sangamo’s proprietary genome-editing technology platform to develop treatments targeting sickle cell disease and beta-thalassemia.
According to Biogen, it will provide Sangamo with an upfront payment of $20 million and will reimburse Sangamo for its internal and external research and development program-related costs. Sangamo may also receive additional payments of approximately $300 million based on the achievement of certain development, regulatory, commercialization and sales milestones, as well as double digit royalties on product sales.
Read the Biogen press release